Industry Updates for the Psychedelics World

Psychedelics News

Industry

21 Mar 2023

Lucy Scientific Acquires Psychedelic Assets from Wesana Health

Last month, a new psychedelic firm joined the major stock exchanges as Lucy Scientific began trading on the NASDAQ....

By Microdose NewsDesk

Industry

17 Mar 2023

Irwin Naturals Backs Out of Deal To Buy Braxia Scientific

Irwin Naturals has backed out of the deal to buy Braxia, terminating the non-binding agreement and Letter of Intent....

By Jason Najum

Industry

16 Mar 2023

Filament Health Announces FDA Approval Of Phase II Clinical Trial

Filament Health Announces FDA Approval Of Phase II Clinical Trial Studying Psilocybin For Methamphetamine Use Disorder...

By Microdose NewsDesk

Industry

15 Mar 2023

Field Trip Health & Wellness to Close Clinics in 5 Locations

In an effort to reduce expenditures, Field Trip Health will close clinics located in Chicago, Washington DC, Seattle, San Diego and Fredericton....

By Microdose NewsDesk

Join Our Newsletter for Exclusive Updates, Stories, and More

Industry

9 Mar 2023

Are LSD and r-MDMA the Future of Psychedelics? MindMed Says Yes

On March 8th, MindMed CEO Robert Barrow spoke for 30 minutes at the 43rd annual Cowen Healthcare Conference....

By James Hallifax

Industry

8 Mar 2023

A Deeper Look at atai Life Sciences’ Corporate Update

atai Life Science has released its most recent corporate update, an opportunity to take a step back and see the full breadth of atai’s diverse set of programs....

By Microdose NewsDesk

Industry

7 Mar 2023

Small Pharma Announces Additional Positive Data From Phase 2a Trial

Today, both patients and investors received additional good news, as Small Pharma has reported supportive data to corroborate its initial Phase 2 trial topline results....

By Microdose NewsDesk

Industry

6 Mar 2023

atai Life Sciences Announces Clinical Pipeline and Corporate Updates

Today we got some clarity as atai Life Sciences released a pipeline update....

By Jason Najum

Industry

6 Mar 2023

The Importance of Cybin’s Next-Generation Psilocybin

Cybin presented data from its ongoing next-generation psilocybin clinical trial during the company’s R&D day....

By James Hallifax

Follow us on social

Latest News

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

Two New Studies Are Rewriting the Rules of Psychedelic Drug Development

Professional Training in Psychedelic Medicine

Psychedelic medicine is reshaping the future of mental health care. From the power of microdosing LSD to the promise of MDMA in PTSD, the world of medical psychedelics offers transformative possibilities. Our comprehensive, CE-accredited course provides you with the knowledge and understanding you need to tap into this groundbreaking field.

WordPress Ads

No Result

View All Result